VVOS

Vivos Therapeutics Inc

• TipRanks·4d ago

  Vivos Therapeutics Regains Nasdaq Compliance After Equity Boost

• Benzinga·5d ago

  Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

• TipRanks·6d ago

  Vivos Therapeutics Acquires Stake in SOD Sciences IP

• Benzinga·6d ago

  Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M

• Benzinga·6d ago

  12 Health Care Stocks Moving In Monday's After-Market Session

• Dow Jones·6d ago

  Press Release: Vivos Therapeutics Closes -2-

• NASDAQ·10/15 15:32

  Vivos Therapeutics Strikes $12M Stock Deal For SOD Sciences Stake And Test Rights

• Seeking Alpha·10/15 13:25

  Vivos Therapeutics to acquire minority stake in SOD Sciences in $12M stock transaction

• TipRanks·10/15 13:23

  Vivos Therapeutics Forms Strategic SOD Sciences Partnership

• TipRanks·10/15 13:11

  Vivos Therapeutics to acquire 11% stake in SOD Sciences for $12M in preferred

• Dow Jones·10/15 13:01

  *Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

• Benzinga·10/15 12:48

  Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M

• Dow Jones·10/15 12:45

  Press Release: Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

• Dow Jones·10/15 12:45

  Press Release: Vivos Therapeutics Agrees to -2-

• TipRanks·09/29 12:50

  Vivos Therapeutics reports progress in material cost reductions, revenue growth